Under the accord, the drug review and drug safety offices now have equal responsibility for "significant safety issues" pertaining to medicines under review or already approved for marketing.
Under the accord, the drug review and drug safety offices will have equal responsibility for "significant safety issues" pertaining to medicines that are under review or have already been approved for marketing.